国际眼科杂志
國際眼科雜誌
국제안과잡지
International Eye Science
2015年
11期
1881-1883
,共3页
康柏西普%黄斑变性%老年%视力
康柏西普%黃斑變性%老年%視力
강백서보%황반변성%노년%시력
conbercept%macular degeneration%age%visual acuity
目的：：观察康柏西普对提高湿性老年性黄斑变性患者视力的临床效果。方法：临床纳入湿性老年性黄斑变性患者70例70眼,根据治疗方案的不同分为研究组与对照组。对照组给予曲安奈德注射液玻璃体腔注射,研究组给予康柏西普注射液玻璃体腔注射。观察两组患者治疗前后裸眼视力变化情况、阅读能力评分、视网膜黄斑色素密度等。结果：治疗后6mo,1a,研究组视力分别为0.47±0.11、0.60±0.14,对照组视力分别为0.27±0.09、0.30±0.15,两组比较差异有统计学意义(P<0.05)；治疗后6mo,1a,研究组黄斑中心凹视网膜厚度分别为336.8±65.4、301.5±76.8μm,对照组黄斑中心凹视网膜厚度分别为379.4±88.2、368.6±81.3μm,两组比较差异有统计学意义(P<0.05)；治疗后6mo,1a,研究组视网膜黄斑色素密度分别为0.19±0.07、0.25±0.09DU；对照组视网膜黄斑色素密度分别为0.12±0.05、0.14±0.05DU,两组比较差异有统计学意义(P<0.05)。结论：玻璃体腔注射康柏西普注射液治疗湿性老年性黄斑变性,具有较好的临床效果,能够显著提高患者裸眼视力,值得推广。
目的：：觀察康柏西普對提高濕性老年性黃斑變性患者視力的臨床效果。方法：臨床納入濕性老年性黃斑變性患者70例70眼,根據治療方案的不同分為研究組與對照組。對照組給予麯安奈德註射液玻璃體腔註射,研究組給予康柏西普註射液玻璃體腔註射。觀察兩組患者治療前後裸眼視力變化情況、閱讀能力評分、視網膜黃斑色素密度等。結果：治療後6mo,1a,研究組視力分彆為0.47±0.11、0.60±0.14,對照組視力分彆為0.27±0.09、0.30±0.15,兩組比較差異有統計學意義(P<0.05)；治療後6mo,1a,研究組黃斑中心凹視網膜厚度分彆為336.8±65.4、301.5±76.8μm,對照組黃斑中心凹視網膜厚度分彆為379.4±88.2、368.6±81.3μm,兩組比較差異有統計學意義(P<0.05)；治療後6mo,1a,研究組視網膜黃斑色素密度分彆為0.19±0.07、0.25±0.09DU；對照組視網膜黃斑色素密度分彆為0.12±0.05、0.14±0.05DU,兩組比較差異有統計學意義(P<0.05)。結論：玻璃體腔註射康柏西普註射液治療濕性老年性黃斑變性,具有較好的臨床效果,能夠顯著提高患者裸眼視力,值得推廣。
목적：：관찰강백서보대제고습성노년성황반변성환자시력적림상효과。방법：림상납입습성노년성황반변성환자70례70안,근거치료방안적불동분위연구조여대조조。대조조급여곡안내덕주사액파리체강주사,연구조급여강백서보주사액파리체강주사。관찰량조환자치료전후라안시력변화정황、열독능력평분、시망막황반색소밀도등。결과：치료후6mo,1a,연구조시력분별위0.47±0.11、0.60±0.14,대조조시력분별위0.27±0.09、0.30±0.15,량조비교차이유통계학의의(P<0.05)；치료후6mo,1a,연구조황반중심요시망막후도분별위336.8±65.4、301.5±76.8μm,대조조황반중심요시망막후도분별위379.4±88.2、368.6±81.3μm,량조비교차이유통계학의의(P<0.05)；치료후6mo,1a,연구조시망막황반색소밀도분별위0.19±0.07、0.25±0.09DU；대조조시망막황반색소밀도분별위0.12±0.05、0.14±0.05DU,량조비교차이유통계학의의(P<0.05)。결론：파리체강주사강백서보주사액치료습성노년성황반변성,구유교호적림상효과,능구현저제고환자라안시력,치득추엄。
Abstract?AlM:To observe the clinical effect of conbercept to improve visual acuity of patients with wet age-related macular degeneration( wAMD) .?METHODS:Seventy patients ( 70 eyes ) with wAMD were selected and divided into study group and control group according to different therapies. The control group received intravitreal injection of triamcinolone acetonide. The study group adopted the intravitreal injection with conbercept. Uncorrected visual acuity, the score of reading ability, the central macular thickness ( CMT) and the macular pigment optical density of two groups before and after treatment was observed.?RESULTS: the visual acuity of study group was 0. 47 ± 0. 11 and 0. 60 ± 0. 14 respectively at 6mo and 1a after treatments, those of control group were 0. 27 ± 0. 09 and 0. 30 ± 0. 15. The differences between the two groups at the two points were statistically significant (P<0. 05). The CMT of study group was 336. 8 ± 65. 4 and 301. 5 ± 76. 8μm respectively at 6mo and 1a after treatments, those of control group were 379. 4 ± 88. 2 and 368. 6 ± 81. 3μm. The differences between the two groups at the two points were statistically significant (P<0. 05). The macular pigment optical density of study group was 0. 19± 0. 07 and 0. 25 ± 0. 09DU respectively at 6mo and 1a after treatments, those of control group were 0. 12 ± 0. 05 and 0. 14±0. 05μm. The differences between the two groups at the two points were statistically significant (P<0. 05).? CONCLUSlON: The intravitreal injection with conbercept has a favorable clinical effect on the treatment of wAMD, Which can greatly improve the uncorrected visual acuity and is worthy promotion.
